15th October 2008

Preclinical Development of Novexatin^® completed

NovaBiotics is delighted to report the successful completion of preclinical development of its lead product, the brush-on (topical) treatment for nail fungus, Novexatin^®/NP213.  This major milestone allows the clinical phase of assessment to begin (subject to regulatory approvals).